Home » Topics » Drugs » Immuno-oncology

Immuno-oncology
RSS

Avax begins phase II study of M-Vax in stage IV metastatic melanoma

April 3, 2000

AltaRex presents clinical plan for OvaRex at BIO 2000 annual meeting

March 30, 2000

SRL-172 associated with significantly improved survival in SCLC patients

March 28, 2000

Phase I clinical study to begin with Reolysin as cancer treatment

March 27, 2000

FDA grants orphan drug status to Zadaxin for treatment of liver cancer

March 24, 2000

Phase I study of AltaRex's BrevaRex MAb completed

March 22, 2000

StressGen initiates phase II study with HspE7 in high-grade cervical dysplasia

March 22, 2000

FDA's ODAC recommends approval of Mylotarg for relapsed AML

March 21, 2000

Picower Institute presents new immunotherapeutic anticancer agents

March 17, 2000

Antisoma takes up another product from ICRF for clinical development

March 17, 2000

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 5, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for May 5, 2026
Axsome’s Auvelity cleared for large Alzheimer’s agitation market
BioWorld
Axsome Therapeutics Inc. won U.S. FDA approval for Auvelity (AXS-05) to treat Alzheimer’s disease agitation, a condition that affects up to three-quarters of...
Bio Korea 2026: US policy risks shift to execution framework
BioWorld
Regulatory uncertainty that dominated the life science sector in 2025 is transitioning into an execution framework for biotechnology companies, provided companies...
Sonire starts US study of cancer HIFU after $18M series A
BioWorld
Sonire Therapeutics Inc. initiated a U.S.-based Sunrise II study of Suizenji, its novel ultrasound-guided high-intensity focused ultrasound (HIFU) system designed...